

# HB-EGF

Catalog # PVGS1687

### Specification

# **HB-EGF - Product Information**

Primary Accession Species Seriola <u>XP\_023257950.1</u>

Sequence Ser88-Leu179

Purity ≥ 90% as analyzed by SDS-PAGE

**Endotoxin Level** < 0.2 EU/ μg of protein by gel clotting method

**Biological Activity** ED<SUB>50</SUB> < 1.0  $\mu$ g/ml, measured by a cell proliferation assay using BALB/3T3 cells, corresponding to a specific activity of > 1.0 × 10<sup>3</sup> units/mg.

Expression System <I>E.coli</I>

**Theoretical Molecular Weight** 10.06 kDa

Formulation

Lyophilized from a 0.2 µm filtered solution in 50 mM Tris, 150 mM Nacl, pH 8.0

**Reconstitution** Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>0 up to 100  $\mu$ g/ml

Storage & Stability

Upon receiving, this product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles.

### **HB-EGF** - Additional Information

**Target Background** 

HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic and chemotactic glycoprotein. An epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It has been shown to play a role in wound healing, cardiac hypertrophy, and heart development and function.

#### **HB-EGF** - **Protein Information**



### HB-EGF - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- <u>Flow Cytomety</u>
- <u>Cell Culture</u>

**HB-EGF** - Images